Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV

Current HIV/AIDS Reports

Volumn 3, Issue 4, 2006, Pages 176-181

  Weiss, Jeffrey J ^a   Gorman, Jack M ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOOD STABILIZER; PAROXETINE; PEGINTERFERON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ANEMIA; ANHEDONIA; ARTHRALGIA; BEHAVIOR DISORDER; BLOOD TOXICITY; CAUSE OF DEATH; CHILL; COGNITIVE DEFECT; COMORBIDITY; CONCENTRATION LOSS; DECREASED APPETITE; DEPRESSION; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER DISEASE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MENTAL DISEASE; MENTAL INSTABILITY; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PSYCHIATRIC TREATMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SUBSTANCE ABUSE; SUICIDAL IDEATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MENTAL DISORDERS; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PSYCHIATRIC STATUS RATING SCALES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33750492618     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-006-0013-2     Document Type: Review

References (46)

1. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
2. Salmon-Ceron D, Lewden C, Morlat P, et al.: Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005, 42:799-805.
3. Miller CL, Wood E, Spittal PM, et al.: The future face of coinfection: prevalence and incidence of HIV and hepatitis C coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004, 36:743-749.
4. Hall CS, Charlebois ED, Hahn JA, et al.: Hepatitis C virus infection in San Francisco's HIV-infected urban poor: high prevalence but low treatment rates. J Gen Intern Med 2004, 19:357-365.
5. Rauch A, Rickenbach M, Weber R, et al.: Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV cohort study. Clin Infect Dis 2005, 41:395-402.
6. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
7. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197-207.
8. Weis N, Lindhardt BO, Kronborg G, et al.: Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006, 42:1482-1487.
9. Soriano V, Pérez-Olmeda M, Rios P, et al.: Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004, 20:351-353.
10. Bräu N: Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother 2005, 56:991-995.
11. Crabb C: Hepatitis C's effect on HIV disease remains elusive despite three new studies. AIDS 2006, 20:N1-N2.
12. Sullivan RS, Hanson DL, Teshale EH, et al: Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006, 20:1171-1179.
13. Braitstein P, Justice A, Bangsberg DR, et al.: Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006, 20:323-331. Finds poorer HIV treatment adherence among HIV/HCV coinfected patients as compared with HIV monoinfected patients, suggesting that adherence is playing a role in the higher mortality rates among HIV/HCV coinfected patients.
14. Lang CA, Conrad S, Garrett L, et al.: Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 2006, 31:335-344.
15. Yun LWH, Maravi M, Kobayashi JS, et al.: Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J AIDS 2005, 38:432-438.
16. Goulet JL, Fultz SL, McGinnis KA, Justice AC: Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005, 19:S99-S105. Documents higher levels of comorbid psychiatric and medical conditions in HIV/HCV coinfected, as compared with HIV monoinfected, US veterans in care in a sample of 25,116 persons.
17. Martin EM, Novak RM, Fendrich M, et al.: Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc 2004, 10:298-300.
18. Ryan EL, Morgello S, Isaacs K, et al.: Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004, 62:957-962.
19. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-876.
20. Schaefer M, Schwaiger M, Pich M, et al.: Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003, 36:5203-5206.
21. Juengling FD, Ebert D, Gut O, et al.: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, 152:383-389.
22. nd: Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006, 40:322-335.
23. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Pegylated alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
24. Laguno M, Blanch J, Murillas J, et al.: Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther 2004, 9:905-909.
25. National Institutes of Health: National Institutes of Health consensus development conference statement: management of hepatitis C. Hepatology 2002, 36(Suppl 1):3-20.
26. Sylvestre DL, Loftis JM, Hauser P, et al.: Co-ocurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004, 81:719-734.
27. Thompson VV, Ragland KE, Hall CS, et al.: Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005, 19:5208-5214. Qualitative and quantitative study of the barriers to treating HCV in coinfected patients as viewed by providers treating HIV/HCV coinfected homeless and marginally housed patients.
28. Edlin BR, Seal KH, Lorvick J, et al.: Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001, 345:211-213.
29. Wagner GJ, Ryan GW: Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. AIDS 2005, 19:S190-S198. Review article which provides a comprehensive overview of the medical and behavioral factors which affect providers' assessment of HCV treatment readiness in coinfected patients and integrates the relevant HIV and HCV study findings.
30. Adeyemi OM, Jensen D, Attar B, et al.: Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS 2004, 18:239-245.
31. Mehta SH, Thomas DL, Sulkowski MS, et al.: A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005, 19:5179-189.
32. Taylor LE, Gholam PM, Schwartzapfel B, Rich JD. Hepatitis C treatment in HIV-HCV-coinfected patients with drug addiction and psychiatric illness: a case report. AIDS Reader 2005, 15:629-638.
33. Strauss SM, Astone JM, Des Jarlais DC, Hagan H: Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS 2005, 19:78-88.
34. McGovern B, Fiore J, Wurcel A, et al.: Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin Infect Dis 2005, 41:S56-S62.
35. Kresina TF, Bruce RD, Cargill VA, Cheever LW: Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis 2005, 41:S83-S88.
36. Conway B, Grebely J, Tossonian H, et al.: A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis, 41:S73-78.
37. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa 2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
38. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
39. Laguno M, Murillas J, Blanco JL, et al.: Peg alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004, 18:F27-F36.
40. Santin M, Shaw E, Garcia MJ, et al.: Efficacy and safety of pegylated interferon-alfa 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2006, 22:315-320.
41. Sola R, Galera JA, Montoliu S, et al.: Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006, 22:393-400.
42. Musselman DL, Lawson DH, Gumnick JF, et al.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
43. Hoffman RG, Cohen MA, Alfonso CA, et al.: Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2004, 44:417-420.
44. Cohen MAA, Alfonso CA: AIDS psychiatry: psychiatric and palliative care, and pain management. In AIDS and Other Manifestations of HIV Infection, edn 4. Edited by Wormser GP. New York: Elsevier; 2004:537-576.
45. McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002, 123:1061-1069.
46. Schaefer M, Schmidt F, Folwaczny C, et al.: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443-451.